https://d2f0ora2gkri0g.cloudfront.net/bkpam2127053_2a77e4d45fd3430f9b7e99239ba49fc0
gallery/istock-1053277490 world news

Latest news

July 3, 2019

Lokon announces a collaboration with Roche to combine LOAd703 with checkpoint blockade antibody treatments in pancreatic cancer and melanoma. See the press release.

October 20, 2018
Jessica Wenthe from Uppsala University presented Lokon Pharma's research at the European Society for Medical Oncology (ESMO) in Munich and was awarded the Best Poster in the immunotherapy session. Congratulations Jessica!

Jessica ESMO award 2018jpg

May 9, 2018
The first patient has been enrolled in the LOAd703 clinical trial in Sweden for the treatment of pancreatic, biliary, colorectal, and ovarian cancer.

January 19, 2017

Our LOAd703 clinical trial for patients with pancreatic cancer in Houston, TX, USA has now treated their first patient!

July 28, 2015

EMA has granted Lokon Pharma an orphan designation status for LOAd703 immunotherapy for the treatment of pancreatic cancer.

May 4, 2015

FDA has granted Lokon Pharma an orphan designation status for LOAd703 immunotherapy for the treatment of pancreatic cancer.